These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 39161385)

  • 1. Epigenetic regulation of NKG2D ligand and the rise of NK cell-based immunotherapy for cancer treatment.
    Kumar R; Gupta R
    Front Oncol; 2024; 14():1456631. PubMed ID: 39161385
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Liu M; Du M; Yu J; Qian Z; Gao Y; Pan W; Zhao X; Wang M; Li H; Zheng J; Huang Q; Wang LM; Xiao H
    Oncoimmunology; 2022; 11(1):2016158. PubMed ID: 35003895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities.
    Diermayr S; Himmelreich H; Durovic B; Mathys-Schneeberger A; Siegler U; Langenkamp U; Hofsteenge J; Gratwohl A; Tichelli A; Paluszewska M; Wiktor-Jedrzejczak W; Kalberer CP; Wodnar-Filipowicz A
    Blood; 2008 Feb; 111(3):1428-36. PubMed ID: 17993609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of CD158 and NKG2A Inhibitory Receptors and Underexpression of NKG2D and NKp46 Activating Receptors on NK Cells in Acute Myeloid Leukemia.
    Sandoval-Borrego D; Moreno-Lafont MC; Vazquez-Sanchez EA; Gutierrez-Hoya A; López-Santiago R; Montiel-Cervantes LA; Ramírez-Saldaña M; Vela-Ojeda J
    Arch Med Res; 2016 Jan; 47(1):55-64. PubMed ID: 26876298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of Polymorphisms of NKG2D Receptor and Its Ligands in Acute Myeloid Leukemia and Human Stem Cell Transplantation.
    Machuldova A; Holubova M; Caputo VS; Cedikova M; Jindra P; Houdova L; Pitule P
    Front Immunol; 2021; 12():651751. PubMed ID: 33868289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chimeric Antigen Receptor T Cells Targeting NKG2D-Ligands Show Robust Efficacy Against Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia.
    Driouk L; Gicobi JK; Kamihara Y; Rutherford K; Dranoff G; Ritz J; Baumeister SHC
    Front Immunol; 2020; 11():580328. PubMed ID: 33384686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of Enhancer of zeste homolog 2 (EZH2) induces natural killer cell-mediated eradication of hepatocellular carcinoma cells.
    Bugide S; Green MR; Wajapeyee N
    Proc Natl Acad Sci U S A; 2018 Apr; 115(15):E3509-E3518. PubMed ID: 29581297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Boosting Natural Killer Cell-Mediated Targeting of Sarcoma Through DNAM-1 and NKG2D.
    Sayitoglu EC; Georgoudaki AM; Chrobok M; Ozkazanc D; Josey BJ; Arif M; Kusser K; Hartman M; Chinn TM; Potens R; Pamukcu C; Krueger R; Zhang C; Mardinoglu A; Alici E; Temple HT; Sutlu T; Duru AD
    Front Immunol; 2020; 11():40. PubMed ID: 32082316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. KLF4-mediated upregulation of the NKG2D ligand MICA in acute myeloid leukemia: a novel therapeutic target identified by enChIP.
    Alkhayer R; Ponath V; Frech M; Adhikary T; Graumann J; Neubauer A; von Strandmann EP
    Cell Commun Signal; 2023 May; 21(1):94. PubMed ID: 37143070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression.
    Zhang X; Rao A; Sette P; Deibert C; Pomerantz A; Kim WJ; Kohanbash G; Chang Y; Park Y; Engh J; Choi J; Chan T; Okada H; Lotze M; Grandi P; Amankulor N
    Neuro Oncol; 2016 Oct; 18(10):1402-12. PubMed ID: 27116977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Leveraging NKG2D Ligands in Immuno-Oncology.
    Fuertes MB; Domaica CI; Zwirner NW
    Front Immunol; 2021; 12():713158. PubMed ID: 34394116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Engineering of chimeric natural killer cell receptors to develop precision adoptive immunotherapies for cancer.
    Obajdin J; Davies DM; Maher J
    Clin Exp Immunol; 2020 Oct; 202(1):11-27. PubMed ID: 32544282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential Effects of Histone Deacetylases on the Expression of NKG2D Ligands and NK Cell-Mediated Anticancer Immunity in Lung Cancer Cells.
    Cho H; Son WC; Lee YS; Youn EJ; Kang CD; Park YS; Bae J
    Molecules; 2021 Jun; 26(13):. PubMed ID: 34203519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contrasting Effects of the Cytotoxic Anticancer Drug Gemcitabine and the EGFR Tyrosine Kinase Inhibitor Gefitinib on NK Cell-Mediated Cytotoxicity via Regulation of NKG2D Ligand in Non-Small-Cell Lung Cancer Cells.
    Okita R; Wolf D; Yasuda K; Maeda A; Yukawa T; Saisho S; Shimizu K; Yamaguchi Y; Oka M; Nakayama E; Lundqvist A; Kiessling R; Seliger B; Nakata M
    PLoS One; 2015; 10(10):e0139809. PubMed ID: 26439264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natural killer cell epigenetic reprogramming in tumors and potential for cancer immunotherapy.
    Hojjatipour T; Maali A; Azad M
    Epigenomics; 2023 Feb; 15(4):249-266. PubMed ID: 37125432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differentiation-promoting drugs up-regulate NKG2D ligand expression and enhance the susceptibility of acute myeloid leukemia cells to natural killer cell-mediated lysis.
    Rohner A; Langenkamp U; Siegler U; Kalberer CP; Wodnar-Filipowicz A
    Leuk Res; 2007 Oct; 31(10):1393-402. PubMed ID: 17391757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors.
    Parihar R; Rivas C; Huynh M; Omer B; Lapteva N; Metelitsa LS; Gottschalk SM; Rooney CM
    Cancer Immunol Res; 2019 Mar; 7(3):363-375. PubMed ID: 30651290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNA demethylation and histone H3K9 acetylation determine the active transcription of the NKG2D gene in human CD8+ T and NK cells.
    Fernández-Sánchez A; Baragaño Raneros A; Carvajal Palao R; Sanz AB; Ortiz A; Ortega F; Suárez-Álvarez B; López-Larrea C
    Epigenetics; 2013 Jan; 8(1):66-78. PubMed ID: 23235109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decitabine has a biphasic effect on natural killer cell viability, phenotype, and function under proliferative conditions.
    Kopp LM; Ray A; Denman CJ; Senyukov VS; Somanchi SS; Zhu S; Lee DA
    Mol Immunol; 2013 Jul; 54(3-4):296-301. PubMed ID: 23328088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natural killer cells in cancer immunotherapy.
    Wang D; Dou L; Sui L; Xue Y; Xu S
    MedComm (2020); 2024 Jul; 5(7):e626. PubMed ID: 38882209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.